Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors
- PMID: 8592247
- DOI: 10.1097/00004872-199509003-00004
Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors
Abstract
Background: A dry cough is the most common adverse effect of angiotensin converting enzyme (ACE) inhibitors, even if it is not particularly serious. Controlled studies have suggested that the incidence may eventually be as high as 20% and the problem seems to occur much more often in women.
Mechanism of ace inhibitor cough: The mechanism of the cough associated with ACE inhibitor treatment is unrelated to inhibition of the renin-angiotensin system because treatment with angiotensin receptor blockers and renin inhibitors has not caused similar problems. Other substrates of ACE have been implicated, and the side effect has been linked in particular to an accumulation of bradykinin or tachykinins in the airways with consequent stimulation of vagal afferents that subserve the cough reflex, particularly the non-myelinated or C fibres. Some of the effects of bradykinin in particular may be due to secondary activation of prostaglandins (PG), especially PGE2 and PGI2. Anecdotal evidence that cyclooxygenase inhibitors prevent the cough has not been sustained in well controlled clinical trials, but recent evidence suggests that inhaled cromoglycate may have a significant inhibitory effect. The mechanism of action of cromoglycate is not well understood but evidence of inhibition of local neural reflexes has been inferred, mostly from animal studies. The observation seems unlikely to have much practical benefit for it is difficult to envisage routine use of an inhaled agent to prevent a drug side effect. The question of whether ACE inhibitors are safe in patients with asthma is still open, and most rechallenge studies have shown little effect on lung function. Data from one large-scale surveillance study suggest that a few individuals may experience dyspnoea and wheezing but no causal relationship has been established.
Conclusion: Delineation of the mechanism of the ACE inhibitor cough may lead to a better understanding of the mechanism of cough in inflammatory airways disease.
Similar articles
-
Cough and inhibition of the renin-angiotensin system.J Hypertens Suppl. 1993 Apr;11(3):S49-52. J Hypertens Suppl. 1993. PMID: 8315520 Review.
-
[Cough, bronchoconstriction and bronchial hyperreactivity in relation to treatment with angiotensin-converting enzyme].Pol Merkur Lekarski. 1999 May;6(35):281-5. Pol Merkur Lekarski. 1999. PMID: 10437403 Review. Polish.
-
ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management.Drug Saf. 1996 Jul;15(1):72-8. doi: 10.2165/00002018-199615010-00006. Drug Saf. 1996. PMID: 8862965 Review.
-
Angiotensin-converting enzyme inhibitor-induced cough: ACCP evidence-based clinical practice guidelines.Chest. 2006 Jan;129(1 Suppl):169S-173S. doi: 10.1378/chest.129.1_suppl.169S. Chest. 2006. PMID: 16428706 Review.
-
Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.J Hum Hypertens. 2002 Dec;16(12):857-63. doi: 10.1038/sj.jhh.1001486. J Hum Hypertens. 2002. PMID: 12522467
Cited by
-
Spectrum of use for the angiotensin-receptor blocking drugs.Curr Hypertens Rep. 1999 Oct;1(5):394-401. doi: 10.1007/s11906-999-0054-1. Curr Hypertens Rep. 1999. PMID: 10981096
-
Zofenopril and incidence of cough: a review of published and unpublished data.Ther Clin Risk Manag. 2011;7:459-71. doi: 10.2147/TCRM.S25976. Epub 2011 Nov 29. Ther Clin Risk Manag. 2011. PMID: 22162922 Free PMC article.
-
Eprosartan: a review of its use in the management of hypertension.Drugs. 2000 Jul;60(1):177-201. doi: 10.2165/00003495-200060010-00009. Drugs. 2000. PMID: 10929934 Review.
-
Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: therapeutic implications.Drugs. 2002;62(7):977-93. doi: 10.2165/00003495-200262070-00001. Drugs. 2002. PMID: 11985486 Review.
-
Late onset asthma: epidemiology, diagnosis and treatment.Drugs Aging. 2000 Nov;17(5):385-97. doi: 10.2165/00002512-200017050-00005. Drugs Aging. 2000. PMID: 11190418 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous